Insys Therapeutics operating loss grows to $11.65 million in October

By Caroline Salls

Pittsburgh, Dec. 20 – Insys Therapeutics, Inc. reported an $11.65 million loss from operations for October on $49,554 in net revenue, according to its monthly operating report filed Friday with the U.S. Bankruptcy Court for the District of Delaware.

In comparison, the company posted a $9.15 million loss from operations for September on $1.98 million in net revenue.

The net loss for October was $36.18 million, widening from a $13.15 million September net loss.

In addition, Insys had $59.04 million in cash and cash equivalents as of Oct. 31, up from $53.67 million at the end of September.

The specialty pharmaceutical company is based in Phoenix. The company filed bankruptcy on June 10, 2019 under Chapter 11 case number 19-11292.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.